Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial

Published:2024-08 Issue: Volume: Page:
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

de Wit Ronald,Vaughn David J.,Fradet Yves,Fong Lawrence,Climent Miguel A.,Necchi Andrea,Petrylak Daniel P.,Gerritsen Winald R.,Gurney Howard,Quinn David I.,Culine Stéphane,Sternberg Cora N.,Bajorin Dean F.,Choueiri Toni K.,Xu Jin,Imai Kentaro,Homet Moreno Blanca,Bellmunt Joaquim,Lee Jae-Lyun

Publisher

Elsevier BV

Reference12 articles.

1. Update on the treatment of metastatic urothelial carcinoma;Bukhari;Sci World J,2018

2. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Powles;Ann Oncol,2022

3. The 2021 Updated European Association of Urology guidelines on metastatic urothelial carcinoma;Cathomas;Eur Urol,2022

4. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017

5. Enfortumab vedotin in previously treated advanced urothelial carcinoma;Powles;N Engl J Med,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP